Published in Blood on October 12, 2011
Molecular Disease Profile of Hematological Malignancies (RELab1) | NCT02459743
GENOMED4ALL: Improving MDS Classification and Prognosis by AI | NCT04889729
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood (2012) 2.50
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood (2015) 1.75
SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov (2013) 1.68
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood (2015) 1.52
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia (2013) 1.44
Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov (2013) 1.39
Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood (2013) 1.34
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia (2012) 1.31
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood (2014) 1.29
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood (2012) 1.29
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica (2012) 1.13
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia (2014) 1.13
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica (2013) 1.11
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun (2015) 1.10
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today (2012) 1.10
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol (2013) 1.06
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica (2012) 1.04
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia (2014) 1.02
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia (2012) 1.02
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia (2015) 1.01
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell (2016) 0.96
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica (2013) 0.96
Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis. Blood (2014) 0.95
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res (2013) 0.95
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia (2014) 0.94
Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol (2012) 0.94
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad Sci U S A (2014) 0.92
Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica (2014) 0.92
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun (2015) 0.92
Subclonal variant calling with multiple samples and prior knowledge. Bioinformatics (2014) 0.91
Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood (2014) 0.88
The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia (2014) 0.88
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica (2012) 0.86
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Rev Bras Hematol Hemoter (2014) 0.85
Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia (2015) 0.85
Genomics of acute myeloid leukemia: the next generation. Front Oncol (2012) 0.84
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Sci (2015) 0.84
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood (2015) 0.82
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol (2013) 0.81
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica (2016) 0.81
Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing. PLoS Genet (2013) 0.81
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Haematologica (2014) 0.81
Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. Leukemia (2015) 0.81
Genomic landscape of megakaryopoiesis and platelet function defects. Blood (2016) 0.81
Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br J Haematol (2015) 0.80
SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. Acta Neuropathol Commun (2016) 0.80
Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells. Leukemia (2013) 0.80
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget (2012) 0.80
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia (2016) 0.79
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget (2016) 0.79
Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. Leuk Lymphoma (2013) 0.79
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
When splicing turns bad. Haematologica (2012) 0.78
Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study. Rev Bras Hematol Hemoter (2016) 0.78
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget (2016) 0.78
Splicing-factor alterations in cancers. RNA (2016) 0.78
The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. BMC Cancer (2015) 0.77
How mRNA is misspliced in acute myelogenous leukemia (AML)? Oncotarget (2014) 0.77
Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Cancer Sci (2014) 0.77
Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex. PLoS Genet (2015) 0.77
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist (2014) 0.77
Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia (2016) 0.77
Aberrant splicing and drug resistance in AML. J Hematol Oncol (2016) 0.76
RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer (2017) 0.75
Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. PLoS One (2015) 0.75
Molecular basis of myelodysplastic syndromes. Leuk Suppl (2012) 0.75
Splicing factor gene mutations in hematologic malignancies. Blood (2016) 0.75
Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. Haematologica (2012) 0.75
Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool. Rambam Maimonides Med J (2014) 0.75
SF3B1/Hsh155 HEAT motif mutations affect interaction with the spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing. Genes Dev (2016) 0.75
It dices, it splices! Blood (2011) 0.75
New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts. Rev Bras Hematol Hemoter (2016) 0.75
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. J Cancer Res Clin Oncol (2017) 0.75
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol (2017) 0.75
Components of the revised International Prognostic Scoring System and outcome after hematopoietic cell transplantation for myelodysplastic syndrome. Blood (2013) 0.75
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk (2016) 0.75
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations. Hematol Rep (2016) 0.75
Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1). Sci Rep (2017) 0.75
Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investig (2017) 0.75
[Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification]. Pathologe (2013) 0.75
SF3B1-Initiating Mutations in MDS with Ring Sideroblasts Target Lymphomyeloid Hematopoietic Stem Cells. Blood (2017) 0.75
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. J Clin Invest (2017) 0.75
Diagnostics and Prognostication of Myelodysplastic Syndromes. Ann Lab Med (2017) 0.75
The clonal origins of leukemic progression of myelodysplasia. Leukemia (2017) 0.75
Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood (2017) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2009) 4.03
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med (2005) 2.94
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med (2009) 2.89
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood (2009) 1.80
TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet (2009) 1.75
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol (2007) 1.64
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One (2008) 1.52
Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood (2002) 1.49
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia (2006) 1.45
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood (2005) 1.44
Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol (2011) 1.42
Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program (2011) 1.38
Ring sideroblasts and sideroblastic anemias. Haematologica (2011) 1.37
Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol (1982) 1.27
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica (2011) 1.25
Natural history of idiopathic refractory sideroblastic anemia. Blood (1988) 1.17
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood (2010) 1.17
Molecular biology of myelodysplastic syndromes. Semin Oncol (2011) 1.01
The dawn of the molecular era of the myelodysplastic syndromes. N Engl J Med (2011) 0.87
Estimation of ferrokinetic parameters by a mathematical model in patients with primary acquired sideroblastic anaemia. Br J Haematol (1978) 0.87
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
The cancer genome. Nature (2009) 23.13
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55